These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1138 related articles for article (PubMed ID: 19596415)

  • 1. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1).
    Yang SG; Wo JE; Li MW; Mi FF; Yu CB; Lv GL; Cao HC; Lu HF; Wang BH; Zhu H; Li LJ
    Vaccine; 2009 Dec; 27(52):7451-8. PubMed ID: 19450640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing immunodominant and protective influenza hemagglutinin epitopes by functional activity and relative binding to major histocompatibility complex class II sites.
    Rajnavölgyi E; Horváth A; Gogolák P; Tóth GK; Fazekas G; Fridkin M; Pecht I
    Eur J Immunol; 1997 Dec; 27(12):3105-14. PubMed ID: 9464794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
    Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
    Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
    Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
    Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
    Treanor JJ; Campbell JD; Zangwill KM; Rowe T; Wolff M
    N Engl J Med; 2006 Mar; 354(13):1343-51. PubMed ID: 16571878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
    Goji NA; Nolan C; Hill H; Wolff M; Noah DL; Williams TB; Rowe T; Treanor JJ
    J Infect Dis; 2008 Sep; 198(5):635-41. PubMed ID: 18694338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice.
    Bodewes R; Kreijtz JH; Hillaire ML; Geelhoed-Mieras MM; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    J Gen Virol; 2010 Jul; 91(Pt 7):1743-53. PubMed ID: 20335492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection.
    Pedersen GK; Madhun AS; Breakwell L; Hoschler K; Sjursen H; Pathirana RD; Goudsmit J; Cox RJ
    J Infect Dis; 2012 Jul; 206(2):158-66. PubMed ID: 22551811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011.
    Moise L; Terry F; Ardito M; Tassone R; Latimer H; Boyle C; Martin WD; De Groot AS
    Hum Vaccin Immunother; 2013 Jul; 9(7):1598-607. PubMed ID: 23846304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enumeration of haemagglutinin-specific CD8+ T cells after influenza vaccination using MHC class I peptide tetramers.
    Kosor Krnic E; Gagro A; Drazenovic V; Kuzman I; Jeren T; Cecuk-Jelicic E; Kerhin-Brkljacic V; Gjenero-Margan I; Kaic B; Rakusic S; Sabioncello A; Markotic A; Rabatic S; Mlinaric-Galinovic G; Dekaris D
    Scand J Immunol; 2008 Jan; 67(1):86-94. PubMed ID: 18052968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells.
    Bot A; Casares S; Bot S; von Boehmer H; Bona C
    J Immunol; 1998 May; 160(9):4500-7. PubMed ID: 9574556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational analysis of proteome of H5N1 avian influenza virus to define T cell epitopes with vaccine potential.
    Parida R; Shaila MS; Mukherjee S; Chandra NR; Nayak R
    Vaccine; 2007 Oct; 25(43):7530-9. PubMed ID: 17900763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on the immunogenicity of adeno-vector vaccine against H5N1 influenza A virus].
    Zhang XG; Li KB; Ma J; Wang NF; Zhang XM; Sang YH; Dong J; Xu H; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr; 23(2):97-9. PubMed ID: 20104746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemagglutinin-specific CD4
    Tan S; Zhang S; Wu B; Zhao Y; Zhang W; Han M; Wu Y; Shi G; Liu Y; Yan J; Wu G; Wang H; Gao GF; Zhu F; Liu WJ
    Vaccine; 2017 Oct; 35(42):5644-5652. PubMed ID: 28917539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
    Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
    Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
    Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.